Do low CD57+ lymphocyte counts indicate chronic Lyme disease?

The relationship between CD57+ lymphocyte counts and chronic Lyme disease is a subject of significant debate within immunology and clinical practice. While some clinicians utilize this marker to assess immune status in persistent Borrelia exposure, the scientific evidence remains mixed regarding its diagnostic specificity and consistency.

Clinical and effectiveness evidence

Evidence for a correlation between low CD57+ counts and chronic Lyme disease is largely derived from observational and cohort studies rather than randomized controlled trials.

• Observational findings: Some studies have identified lower CD3−CD57+ natural killer (NK) cell counts in patients reporting persistent symptoms after initial antibiotic therapy compared to healthy controls. One cohort analysis observed low CD57+ counts in approximately 59% of tested Lyme cases.
• Controlled study conflicts: In contrast, rigorously controlled studies focusing on Post-Treatment Lyme Disease Syndrome (PTLDS) have failed to replicate these findings, showing no significant difference in CD57+ counts between PTLDS patients and healthy individuals.
• Specificity concerns: CD57+ levels are not unique to Borrelia exposure. Reductions are seen in various chronic infections (such as Cytomegalovirus) and during the natural aging process, which limits the marker's utility as a standalone diagnostic tool for Lyme disease.

Mechanistic explanations

The biological plausibility of this claim rests on the specific role CD57+ cells play in the innate and adaptive immune systems.

• Marker of maturity: CD57 is a carbohydrate epitope expressed on terminally differentiated, mature NK cells and CD8+ T cells. These cells represent a potent effector population with high cytotoxic capacity.
• Cytotoxic function: CD57+ NK cells are characterized by increased release of perforin and granzymes, alongside significant production of Interferon-gamma (IFN-γ). These are the primary tools the immune system uses to eliminate intracellular pathogens and infected cells.
• Surveillance impairment: A reduction in these cells mechanistically implies a decrease in the body's immediate, antigen-specific cytotoxic response. In the context of Borrelia, it is hypothesized that the bacteria may induce immune shifts or cellular exhaustion, leading to a deficiency in this effector subset and potentially facilitating pathogen persistence or immune evasion.

Clinical implications

For a 30-year-old female, interpreting CD57+ counts requires caution and integration with other clinical data.

• Diagnostic utility: Low CD57+ counts are not currently recognized as a definitive biomarker for Lyme disease in standard clinical guidelines.
• Holistic assessment: If used, the marker should be viewed as one piece of a broader immunological profile, acknowledging that "low" levels may reflect general immune activation or exhaustion rather than a specific bacterial trigger.

Bottom line

The claim that low CD57+ counts correlate with chronic Lyme disease and reflect impaired surveillance is plausible based on the biological role of these cells in cytotoxicity. However, it is not consistently supported by scientific evidence due to a lack of specificity and conflicting results in controlled clinical trials.